Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Celgene extends exclusivity period with Agios
January 2015
SHARING OPTIONS:

CAMBRIDGE, Mass.—Under a global strategic collaboration agreement with Agios Pharmaceuticals Inc., Celgene Corp. has extended its exclusivity period for an additional year to April 2016. The companies have been collaborating since April 2010 for the discovery, development and commercialization of disease-altering cancer therapies stemming from Agios’ cancer metabolism research platform. Celgene will maintain its exclusive option to drug candidates resulting from Agios’ platform through April 2016, for which Agios will receive $20 million. The extension marks the final year for the discovery phase of the collaboration under the original terms. This follows another development in June of this year when Celgene exercised its exclusive option to license AG-221, a drug candidate nominated during the discovery phase of the collaboration, thereby gaining worldwide development and commercialization rights for the compound, though Agios continues to conduct early clinical development activities in the AG-221 development program.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.